FLORTAUCIPIR F 18


Synonyms	(F-18)T807 18F-AV-1451 AV-1451 F-18 Flortaucipir (18f) Flortaucipir f 18 Flortaucipir f-18 LY-3191748 LY3191748 T-807 F-18 T807 F-18 Tauvid [F-18]T807
Status
Molecule Category	UNKNOWN
UNII	T1JP1KYU9O


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	GETAAWDSFUCLBS-SJPDSGJFSA-N
Smiles	[18F]c1ccc(-c2ccc3c(c2)[nH]c2ccncc23)cn1
InChI	InChI=1S/C16H10FN3/c17-16-4-2-11(8-19-16)10-1-3-12-13-9-18-6-5-14(13)20-15(12)7-10/h1-9,20H/i17-1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C16H10FN3
Molecular Weight	262.28
AlogP	3.92
Hydrogen Bond Acceptor	2.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	1.0
Polar Surface Area	41.57
Molecular species	NEUTRAL
Aromatic Rings	4.0
Heavy Atoms	20.0

Bioactivity

Mechanism of Action	Action	Reference
Diagnostic agent	None	FDA

Related Entries

Cross References

Resources	Reference
ChEMBL	CHEMBL3545253
DrugBank	DB14914
FDA SRS	T1JP1KYU9O
Guide to Pharmacology	9100
SureChEMBL	SCHEMBL13640613

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).